Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
through the end of the decade, and CEO Christopher Viehbacher says the company is entering a "whole new era of growth" even as it has cut R&D spending by about 25% over three years to reallocate resources toward launch and medical activities. Leqembi's complex launch is being simplified via approved blood-based diagnostics (raising appropriate-treatment yield from ~50% to ~70%), a subcutaneous maintenance form already approved and a subcutaneous induction under priority review (decision expected May 24), with Part D coverage timing that could affect availability in 2027. Biogen will be selective on M&A , focusing on assets with nearer-term launch potential because replacing $1 billion of after-tax profit could require $15–$20 billion in deals; near-term growth is expected to come from recent launches (Leqembi, QALSODY, ZURZUVAE, SKYCLARYS) while legacy MS products face continued competitive erosion and a mid-single-digit revenue decline is guided for 2026. Interested in Biogen I
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- What Makes Biogen (BIIB) an Attractive Long-Term Holding? [Yahoo! Finance]Yahoo! Finance
- Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences [Yahoo! Finance]Yahoo! Finance
- Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe ConferencesGlobeNewswire
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome [Yahoo! Finance]Yahoo! Finance
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet SyndromeGlobeNewswire
BIIB
Earnings
- 2/9/26 - Beat
BIIB
Sec Filings
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- BIIB's page on the SEC website